Notice of Continuation and Expansion of a Disease Management Demonstration Project for TRICARE Standard Beneficiaries, 11089-11090 [E9-5626]

Download as PDF Federal Register / Vol. 74, No. 49 / Monday, March 16, 2009 / Notices Avenue, NW, Washington, DC 20230, in Room 4830. The seminar will present climate data, services, and programs available from the U.S. Department of Commerce for U.S. companies coming to terms with climate variability. The agenda will feature strategies for sustainability, competitiveness, and networking for the business community. DATES: The meeting will begin at 8:30 a.m. on Wednesday, April 1, 2009, recess at 3:00 p.m. ADDRESSES: Department of Commerce, 14th and Constitution NW, Washington DC 20230, Room 4830. FOR FURTHER INFORMATION CONTACT: To register, please email your name, company name, contact information including email and phone number to: April1.Conference@mail.doc.gov. For further information, phone Ellen Bohon, Office of Energy and Environmental Technologies Industries (OEEI), International Trade Administration, U.S. Department of Commerce at (202) 482–0359. SUPPLEMENTARY INFORMATION: Special Accommodations This meeting is physically accessible to people with disabilities. Requests for sign language interpretation or other auxiliary aids should be directed to (202) 482–0359. Dated: March 10, 2009. Captain Todd Stiles, Executive Director, Office of the Deputy Under Secretary, National Oceanic and Atmospheric Administration. [FR Doc. E9–5640 Filed 3–13–09; 8:45 am] BILLING CODE 3510–12–S CORPORATION FOR NATIONAL AND COMMUNITY SERVICE Information Collection; Emergency Submission for OMB Review, Comment Request AGENCY: Corporation for National and Community Service. ACTION: Notice. SUMMARY: The Corporation for National and Community Service (hereinafter the ‘‘Corporation’’), has submitted an emergency public information collection request (ICR) entitled AmeriCorps VISTA Recovery Act Progress Report Supplement to the Office of Management and Budget (OMB) for review and approval within seven days of submission. This action is being implemented in accordance with OMB guidance and the Paperwork Reduction Act of 1995, Public Law 104– 13, (44 U.S.C. Chapter 35). A copy of VerDate Nov<24>2008 15:38 Mar 13, 2009 Jkt 217001 this ICR, with applicable supporting documentation may be obtained by contacting the Corporation for National Service, AmeriCorps VISTA, Craig Kinnear, Program Analyst, (202) 606– 6708, or by e-mail at ckinnear@cns.gov. Individuals who use a telecommunications device for the deaf (TTY–TDD) may call (202) 565–2799 between 8:30 a.m. and 5 p.m. Eastern Time, Monday through Friday. ADDRESSES: You may submit comments, identified by the title of the information collection activity, to (1) Corporation for National and Community Service, and (2) the Office of Information and Regulatory Affairs. Please send comments to: (1) Corporation for National and Community Service, Attn: Craig Kinnear, Program Analyst, AmeriCorps VISTA by any of the following two methods within 30 days from the date of publication in this Federal Register: (a) By fax to: (202) 606–3475 Attention: Craig Kinnear, Program Analyst, AmeriCorps VISTA; and (b) Electronically by e-mail to ckinnear@cns.gov. and (2) Office of Information and Regulatory Affairs, Attn: Ms. Sharon Mar, OMB Desk Officer for the Corporation for National and Community Service, by any of the following two methods within 30 days from the date of publication in this Federal Register: (a) By fax to: (202) 395–6974, Attention: Ms. Sharon Mar, OMBH Desk Officer for the Corporation for National and Community Service; and (b) Electronically by e-mail to smar@omb.eop.gov. SUPPLEMENTARY INFORMATION: The OMB is particularly interested in comments which: • Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the Corporation, including whether the information will have practical utility; • Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; • Propose ways to enhance the quality, utility and clarity of the information to be collected; and, • Propose ways to minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology (e.g., permitting electronic submissions of responses). PO 00000 Frm 00012 Fmt 4703 Sfmt 4703 11089 Current Action The Corporation seeks to enhance data elements collected via these information collection tools. Type of Review: New. Agency: Corporation for National and Community Service. Title: VISTA Recovery Act Progress Report Supplement. OMB Number: New. Agency Number: None. Affected Public: AmeriCorps*VISTA sponsoring organizations (includes nonprofit organizations and state, local and tribal agencies). Total Respondents: 950. Frequency: Quarterly. Average Time per Response: 1 hour. Estimated Total Burden Hours: 3,800. Total Burden Cost (capital/startup): None. Total Burden Cost (operating/ maintenance): None. Dated: March 11, 2009. Paul Davis, Acting Director, AmeriCorps*VISTA. [FR Doc. E9–5669 Filed 3–13–09; 8:45 am] BILLING CODE 6050–$$–P DEPARTMENT OF DEFENSE Office of the Secretary Notice of Continuation and Expansion of a Disease Management Demonstration Project for TRICARE Standard Beneficiaries Department of Defense. Notice of demonstration project. AGENCY: ACTION: SUMMARY: This notice is to advise interested parties of the continuation and expansion of a Military Health System (MHS) demonstration project entitled ‘‘Disease Management Demonstration Project for TRICARE Standard Beneficiaries’’. The original demonstration notice was published on June 13, 2007 (72 FR 32628–32629) and described a demonstration project to provide disease management (DM) services to TRICARE Standard beneficiaries in addition to the TRICARE Prime beneficiaries who were already entitled to such services. TRICARE began the demonstration project in March 2007 for Standard beneficiaries and this demonstration project has enabled the MHS to provide uniform policies and practices on disease and chronic care management throughout the TRICARE network. Additionally, the demonstration has helped determine the effectiveness of DM programs in improving the health status of beneficiaries with targeted E:\FR\FM\16MRN1.SGM 16MRN1 11090 Federal Register / Vol. 74, No. 49 / Monday, March 16, 2009 / Notices chronic diseases or conditions, and any associated cost savings. The TRICARE Management Activity (TMA) chose a phased approach to determine the efficacy and cost effectiveness of its disease management demonstration, beginning with beneficiaries identified with the disease states of asthma, congestive heart failure, and diabetes. TMA now intends to expand the disease management services to TRICARE Standard beneficiaries with the additional disease states of cancer, Chronic Obstructive Pulmonary Disease (COPD), and anxiety and depression disorders as well as continue the original disease states of asthma, congestive heart failure, and diabetes. This expansion and continuation of the DM demonstration project will be conducted under the authority provided in 10 U.S.C. 1092. DATES: The expansion of the demonstration will be effective April 1, 2009 and will continue for a period of 2 years until March 31, 2011. The terms and conditions of the original demonstration notice will continue. FOR FURTHER INFORMATION CONTACT: Dr. Barry Cohen, Director of Healthcare Operations—TRICARE Management Activity, 5111 Leesburg Pike, Suite 810, Falls Church, VA 22041–3206; telephone (703) 681–4029. SUPPLEMENTARY INFORMATION: A. Background For additional information on the TRICARE demonstration project for DM, please see 72 FR 32628–32629. The demonstration notice focused on explaining the differences between the DM benefits available to TRICARE Standard and TRICARE Prime beneficiaries and the manner in which DM services had been provided prior to the demonstration. The prior notice explained that for purposes of the demonstration, the Department of Defense (DoD) would waive, for these DM services provided to Standard beneficiaries, the provisions of 10 U.S.C. 1079(a)(13) and 32 CFR 199.4(g)(39) that expressly exclude clinical preventive services for TRICARE Standard beneficiaries. The prior notice also explained the enrollment process and cap on DM costs. B. Description of Expansion of Demonstration Project Under this demonstration, DoD has waived, for disease management services provided to TRICARE Standard beneficiaries, the provisions of 10 U.S.C. 1079(a)(13) and 32 CFR 199.4(g)(39) that expressly exclude clinical preventive services for TRICARE Standard VerDate Nov<24>2008 15:38 Mar 13, 2009 Jkt 217001 beneficiaries in the current benefit. The Military Health System (MHS) has enrolled TRICARE Standard beneficiaries in its DM programs. DM services provided to Standard beneficiaries have included, but have not been limited to: Clinical preventive examinations, patient education and counseling services, and periodic screening exams. MHS DM program costs have been capped not to exceed the amount approved by the contracting officer. The DM program costs are total costs of DM services provided to both Prime and Standard beneficiaries. Only those beneficiaries identified by the TRICARE Management Activity (TMA) for disease management of asthma, congestive heart failure, and diabetes have been included in the current program. TMA is now expanding the demonstration by including the additional disease states of cancer, COPD, and anxiety and depression disorders. Beneficiaries identified by TMA are included in the DM program unless they choose to opt out. This action directly reduces variation across the system and results in improved consistency and quality for beneficiaries with targeted chronic illness, regardless of TRICARE classification. Furthermore, including TRICARE Standard beneficiaries in current DM efforts informs the MHS about total potential savings and return on investment (ROI) associated with DM, a stated requirement of the John Warner National Defense Authorization Act for Fiscal Year 2007. Continuing to provide the current three, and adding the additional three diseases to the systemwide DM program, will improve the quality of care of our beneficiaries. By educating patients about their disease and helping them manage their symptoms, many of the complications of these diseases can be avoided, possibly slowing the progression of their chronic disease, thus resulting in significant cost savings. C. Implementation The expansion of the demonstration will be effective on April 1, 2009. The terms and conditions of the original demonstration as provided in the Notice in 72 FR 32368–32369 will continue on that date. D. Evaluation An independent evaluation of the demonstration will be conducted. The evaluation will be designed to use a combination of administrative and survey measures of health care outcomes (clinical, utilization, financial, and humanistic measures) to provide analyses and comment on meeting its PO 00000 Frm 00013 Fmt 4703 Sfmt 4703 goal of providing uniform disease management policies and practices across the MHS. Dated: March 9, 2009. Patricia L. Toppings, OSD Federal Register Liaison Officer, Department of Defense. [FR Doc. E9–5626 Filed 3–13–09; 8:45 am] BILLING CODE 5001–06–P DEPARTMENT OF DEFENSE Office of the Secretary Defense Science Board Department of Defense. Notice of advisory committee meetings. AGENCY: ACTION: SUMMARY: The Defense Science Board will meet in closed session on May 13– 14, 2009; at the Pentagon, Arlington, VA. The mission of the Defense Science Board is to advise the Secretary of Defense and the Under Secretary of Defense for Acquisition, Technology & Logistics on scientific and technical matters as they affect the perceived needs of the Department of Defense. At this meeting, the Board will discuss interim finding and recommendations resulting from ongoing Task Force activities. The Board will also discuss plans for future consideration of scientific and technical aspects of specific strategies, tactics, and policies as they may affect the U. S. national defense posture and homeland security. FOR FURTHER INFORMATION CONTACT: Ms. Debra Rose, Executive Officer, Defense Science Board, 3140 Defense Pentagon, Room 3B888A, Washington, DC 20301– 3140, via e-mail at debra.rose@osd.mil, or via phone at (703) 571–0084. SUPPLEMENTARY INFORMATION: In accordance with section 10(d) of the Federal Advisory Committee Act, Public Law No. 92–463, as amended (5 U.S.C. App. 2) and 41 CFR 102–3.155, the Department of Defense has determined that these Defense Science Board Quarterly meeting will be closed to the public. Specifically, the Under Secretary of Defense (Acquisition, Technology and Logistics), with the coordination of the DoD Office of General Counsel, has determined in writing that all sessions of these meetings will be closed to the public because they will be concerned throughout with matters listed in 5 U.S.C. 552b(c)(1). Interested persons may submit a written statement for consideration by the Defense Science Board. Individuals submitting a written statement must submit their statement to the Designated Federal Official at the address detailed E:\FR\FM\16MRN1.SGM 16MRN1

Agencies

[Federal Register Volume 74, Number 49 (Monday, March 16, 2009)]
[Notices]
[Pages 11089-11090]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-5626]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Notice of Continuation and Expansion of a Disease Management 
Demonstration Project for TRICARE Standard Beneficiaries

AGENCY: Department of Defense.

ACTION: Notice of demonstration project.

-----------------------------------------------------------------------

SUMMARY: This notice is to advise interested parties of the 
continuation and expansion of a Military Health System (MHS) 
demonstration project entitled ``Disease Management Demonstration 
Project for TRICARE Standard Beneficiaries''. The original 
demonstration notice was published on June 13, 2007 (72 FR 32628-32629) 
and described a demonstration project to provide disease management 
(DM) services to TRICARE Standard beneficiaries in addition to the 
TRICARE Prime beneficiaries who were already entitled to such services. 
TRICARE began the demonstration project in March 2007 for Standard 
beneficiaries and this demonstration project has enabled the MHS to 
provide uniform policies and practices on disease and chronic care 
management throughout the TRICARE network. Additionally, the 
demonstration has helped determine the effectiveness of DM programs in 
improving the health status of beneficiaries with targeted

[[Page 11090]]

chronic diseases or conditions, and any associated cost savings. The 
TRICARE Management Activity (TMA) chose a phased approach to determine 
the efficacy and cost effectiveness of its disease management 
demonstration, beginning with beneficiaries identified with the disease 
states of asthma, congestive heart failure, and diabetes. TMA now 
intends to expand the disease management services to TRICARE Standard 
beneficiaries with the additional disease states of cancer, Chronic 
Obstructive Pulmonary Disease (COPD), and anxiety and depression 
disorders as well as continue the original disease states of asthma, 
congestive heart failure, and diabetes. This expansion and continuation 
of the DM demonstration project will be conducted under the authority 
provided in 10 U.S.C. 1092.

DATES: The expansion of the demonstration will be effective April 1, 
2009 and will continue for a period of 2 years until March 31, 2011. 
The terms and conditions of the original demonstration notice will 
continue.

FOR FURTHER INFORMATION CONTACT: Dr. Barry Cohen, Director of 
Healthcare Operations--TRICARE Management Activity, 5111 Leesburg Pike, 
Suite 810, Falls Church, VA 22041-3206; telephone (703) 681-4029.

SUPPLEMENTARY INFORMATION:

A. Background

    For additional information on the TRICARE demonstration project for 
DM, please see 72 FR 32628-32629. The demonstration notice focused on 
explaining the differences between the DM benefits available to TRICARE 
Standard and TRICARE Prime beneficiaries and the manner in which DM 
services had been provided prior to the demonstration. The prior notice 
explained that for purposes of the demonstration, the Department of 
Defense (DoD) would waive, for these DM services provided to Standard 
beneficiaries, the provisions of 10 U.S.C. 1079(a)(13) and 32 CFR 
199.4(g)(39) that expressly exclude clinical preventive services for 
TRICARE Standard beneficiaries. The prior notice also explained the 
enrollment process and cap on DM costs.

B. Description of Expansion of Demonstration Project

    Under this demonstration, DoD has waived, for disease management 
services provided to TRICARE Standard beneficiaries, the provisions of 
10 U.S.C. 1079(a)(13) and 32 CFR 199.4(g)(39) that expressly exclude 
clinical preventive services for TRICARE Standard beneficiaries in the 
current benefit. The Military Health System (MHS) has enrolled TRICARE 
Standard beneficiaries in its DM programs. DM services provided to 
Standard beneficiaries have included, but have not been limited to: 
Clinical preventive examinations, patient education and counseling 
services, and periodic screening exams. MHS DM program costs have been 
capped not to exceed the amount approved by the contracting officer. 
The DM program costs are total costs of DM services provided to both 
Prime and Standard beneficiaries. Only those beneficiaries identified 
by the TRICARE Management Activity (TMA) for disease management of 
asthma, congestive heart failure, and diabetes have been included in 
the current program. TMA is now expanding the demonstration by 
including the additional disease states of cancer, COPD, and anxiety 
and depression disorders. Beneficiaries identified by TMA are included 
in the DM program unless they choose to opt out. This action directly 
reduces variation across the system and results in improved consistency 
and quality for beneficiaries with targeted chronic illness, regardless 
of TRICARE classification. Furthermore, including TRICARE Standard 
beneficiaries in current DM efforts informs the MHS about total 
potential savings and return on investment (ROI) associated with DM, a 
stated requirement of the John Warner National Defense Authorization 
Act for Fiscal Year 2007. Continuing to provide the current three, and 
adding the additional three diseases to the system-wide DM program, 
will improve the quality of care of our beneficiaries. By educating 
patients about their disease and helping them manage their symptoms, 
many of the complications of these diseases can be avoided, possibly 
slowing the progression of their chronic disease, thus resulting in 
significant cost savings.

C. Implementation

    The expansion of the demonstration will be effective on April 1, 
2009. The terms and conditions of the original demonstration as 
provided in the Notice in 72 FR 32368-32369 will continue on that date.

D. Evaluation

    An independent evaluation of the demonstration will be conducted. 
The evaluation will be designed to use a combination of administrative 
and survey measures of health care outcomes (clinical, utilization, 
financial, and humanistic measures) to provide analyses and comment on 
meeting its goal of providing uniform disease management policies and 
practices across the MHS.

    Dated: March 9, 2009.
Patricia L. Toppings,
OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. E9-5626 Filed 3-13-09; 8:45 am]
BILLING CODE 5001-06-P